Overview

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Phase:
Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
National Institutes of Health (NIH)
Treatments:
Acalabrutinib